The value of oncology drugs is of great interest to patients, physicians, payers and policymakers. Spending on oncology treatments is increasing faster as the number of cancer patients continues to increase and patients are living longer. In the U.S, health care reform efforts are bringing areas of high expense – like oncology drugs - under scrutiny. That means oncology manufacturers must prove the value of their products to many stakeholders.
The ZS Oncology Value Watchdog Report summarizes issues related to ongoing discussions about value. It provides insights about the definition of value, as well as frame works and perspectives for assessing value.